Latest News

New Client Win: Aagami Appointed by Biopharma Innovator for Out-Licensing of Market-Approved, First-in-Class Antimicrobial Peptide (AMP) Spray

CHICAGO, IL - September 01, 2026 - Aagami, Inc. is pleased to announce a strategic new client win: we have been appointed by a venture-backed bio...

Published : 01 Sep 2026

Read More

U.S. Bankruptcy Court Approves Contract Extension for Aagami as Exclusive Advisory Consultant for Cytometix Asset Disposition

CHICAGO, IL — August 01, 2026 — Aagami, Inc., a premier life sciences management consulting firm based in the Chicago area, announced today t...

Published : 01 Aug 2026

Read More

New Client Win: Aagami Appointed by Belgian Biopharma Innovator to Secure Commercialization Partners for CE-Marked Knee Osteoarthritis Implant

CHICAGO, IL - July 07, 2026: Aagami is pleased to announce a new client win: we have been appointed by an innovative biopharmaceutical company ba...

Published : 07 Jul 2026

Read More

New Client Win: Aagami Appointed to Secure Strategic Partnerships, Licensing, and Funding for Phase 3-Ready Cardiovascular Asset Targeting Atrial Fibrillation

CHICAGO, IL — July 2, 2026 — Aagami, Inc., a premier global life sciences consulting firm, today announced it has been appointed by an innova...

Published : 02 Jul 2026

Read More

New Client Win: Aagami Appointed by Innovative Biopharmaceutical Company to Secure Strategic Partnering and Global Licensing for Advanced Oncology and Rare Disease Pipelines

CHICAGO, IL — July 1, 2026 — Aagami, Inc., a premier global life sciences consulting firm, is proud to announce a new client win. An innovati...

Published : 01 Jul 2026

Read More

Aagami Appointed to Secure Exclusive Regional Partners in Japan and South Korea for Advanced Neurosurgical MRI and Robotics

CHICAGO, IL — June 19, 2026 — Marking its second major East Asian partnering mandate in the medical technology sector this week, Aagami, Inc....

Published : 19 Jun 2026

Read More

Aagami Secures New Strategic Assignment from existing client to expand into Japan and Korea for Advanced Urological MRI and Prostate Interventions

CHICAGO, IL — June 18, 2026 — Aagami, Inc. has received a new strategic assignment from a highly valued existing client. Under this expanded ...

Published : 18 Jun 2026

Read More

New Client Win: Aagami Selected to Lead Outlicensing for Key Biosimilars in Japan and South Korea

Aagami is proud to announce a New Client Win. We have been officially appointed by a prominent, rapidly growing global pharmaceutical company to ...

Published : 16 Jun 2026

Read More

Aagami Wins New Project from French Biotech Client

Aagami has been awarded a new mandate by its French biotech client to support the out-licensing of NFL-101, the client’s lead Phase 3 asset for smok...

Published : 01 Jun 2026

Read More

Aagami Secures Global Strategic Advisory Mandate from existing Client for Phase 3-Ready Cardiovascular Biologic

Aagami, Inc., a boutique global life science strategic consulting firm, has been awarded an exclusive, unrestricted global advisory assignment by a pr...

Published : 01 Jun 2026

Read More